{
  "trial_id": "NCT02623647",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "age",
      "label": "met",
      "evidence": "63-year-old man"
    },
    {
      "criterion": "low risk prostate cancer",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Gleason Score-GLS: 3+3 and serum Prostate Specific Antigen-PSA: PSA<10 ng/ml",
      "label": "met",
      "evidence": "PSA level: 3.5 ng/mL"
    },
    {
      "criterion": "intermediate risk prostate cancer defined as clinical stage T2b-c or GLS 7",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "PSA of 10-20 ng/ml, only patients with favourable characteristics: a single factor for intermediate risk AND GLS 3 + 4 AND <50% of biopsy cores containing cancer (12 cores as a minimum)",
      "label": "met",
      "evidence": ""
    }
  ],
  "exclusion": [
    {
      "criterion": "prior radiotherapy",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "concomitant androgen deprivation",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "pt failure to consent",
      "label": "met",
      "evidence": ""
    }
  ],
  "notes": "",
  "_meta": {
    "topic_id": "60",
    "trial_id": "NCT02623647",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}